PHILADELPHIA, May 14, 2013 – The IP & Science business of Thomson Reuters, the world’s leading provider of intelligent information for businesses and professionals, today announced the release of a life sciences report, “An Outlook on U.S. Biosimilar Competition,” providing a comprehensive view of the challenges facing companies entering the United States biosimilar drug market and key players predicted to break into this developing pharmaceutical space.
While the U.S. continues to take steps toward entering the global biosimilar market, it lags behind other nations in this space. The report compares U.S. and EU regulations to underscore the significant differences between these regions and explore ways the U.S. can compete more effectively, in addition to reviewing emerging regulatory developments in India and China. It also identifies potential leaders of the U.S. market, including Amgen, Hospira and Sandoz, among the top pharmaceutical companies with the most potential to dominate the early stages of biosimilar medications entering the U.S.
Biologic medicines, including biosimilars, are developed using living organisms instead of synthesized chemical compounds and are known to effectively treat a range of conditions including rheumatoid arthritis, metastatic breast cancer, non-Hodgkin lymphoma and anemia. Innovative biologic treatments can cost tens of thousands of dollars per year. Competition from biosimilar therapies will help to lower the cost of these expensive treatments, thus helping to reduce healthcare costs and increase patient access.
“This report is a prime example of the insight that can be gleaned by our internal experts using our high quality, curated life sciences data” said Jon Brett-Harris, managing director, Thomson Reuters Life Sciences. “Our goal is to provide cutting-edge information and solutions to support our clients making confident decisions related to drug discovery, development and delivery.”
“An Outlook on U.S. Biosimilar Competition” was created by Thomson Reuters experts in generic drug and API intelligence. The team utilized Newport PremiumTM, the industry’s leading tool for identifying and evaluating generic drug development and licensing opportunities, to compile the report.
View “An Outlook on U.S. Biosimilar Competition.”
Learn more about Thomson Reuters Generic and API Intelligence and Newport Premium.
Thomson Reuters is the world's leading source of intelligent information for businesses and professionals. We combine industry expertise with innovative technology to deliver critical information to leading decision makers in the financial and risk, legal, tax and accounting, intellectual property and science and media markets, powered by the world's most trusted news organization. With headquarters in New York and major operations in London and Eagan, Minn., Thomson Reuters employs approximately 60,000 people and operates in over 100 countries. Thomson Reuters shares are listed on the Toronto and New York Stock Exchanges. For more information, go to www.thomsonreuters.com.